Veterinary Pathology, Vol 33, Issue 2 213-221, Copyright © 1996 by American College of Veterinary Pathologists

ARTICLES

p53 tumor suppressor protein overexpression in osteogenic tumors of dogs

J. E. Sagartz, W. L. Bodley, R. M. Gamblin, C. G. Couto, L. A. Tierney and C. C. Capen
Department of Veterinary Biosciences, College of Veterinary Medicine, Ohio State University, Columbus, USA.

Alterations in the p53 tumor suppressor gene have been implicated in the genesis and/or progression of the majority of human cancers, including osteosarcoma. Stabilization of the protein by mutation or interaction with other proteins prolongs its half-life, rendering it detectable by immunohistochemistry. Osteosarcoma is the most common primary canine bone tumor and is characterized by frequent early metastases. Multilobular tumors of bone involve primarily flat bones of the head and are low-grade malignancies with lower metastatic potential. The objectives of this study were to determine the prevalence of p53 protein overexpression in 106 osteogenic tumors of dogs using an indirect immunohistochemical method and to compare p53 overexpression between tumors with different clinical behavior. A polyclonal p53 antibody (CM-1) served as the primary antibody. Tumors were scored based upon an estimate of the percentage of tumor cells stained. Significant differences in the prevalence of overexpression were observed between osteosarcomas (72%) and multilobular tumors of bone (20%, P = 0.0020). Osteosarcomas of the appendicular skeleton had a significantly higher prevalence of p53 overexpression (84%) than did osteosarcomas of the axial skeleton (56%, P = 0.0060). Our results show that p53 tumor suppressor protein is overexpressed in the majority of canine osteosarcomas. The higher prevalence of overexpression in osteosarcomas versus multilobular tumors of bone and in osteosarcomas of the appendicular skeleton versus those of the axial skeleton suggests that alterations in p53 expression correlate with highly aggressive tumor behavior.

This article has been cited by other articles:

				A. E. Hershey, R. R. Dubielzig, M. L. Padilla, and S. C. Helfand Aberrant p53 Expression in Feline Vaccine-associated Sarcomas and Correlation with Prognosis Vet. Pathol., November 1, 2005; 42(6): 805 - 811. [Abstract] [Full Text] [PDF]

				P. Loukopoulos, J. R. Thornton, and W. F. Robinson Clinical and Pathologic Relevance of p53 Index in Canine Osseous Tumors Vet. Pathol., May 1, 2003; 40(3): 237 - 248. [Abstract] [Full Text] [PDF]

				K. Kahnt, K. Matz-Rensing, P. Hofmann, C. Stahl-Hennig, and F.-J. Kaup SIV-associated Lymphomas in Rhesus Monkeys (Macaca mulatta) in Comparison with HIV-associated Lymphomas Vet. Pathol., January 1, 2002; 39(1): 42 - 55. [Abstract] [Full Text] [PDF]

				P. E. Ginn, L. E. Fox, J. C. Brower, A. Gaskin, I. D. Kurzman, and P. S. Kubilis Immunohistochemical Detection of p53 Tumor-Suppressor Protein is a Poor Indicator of Prognosis for Canine Cutaneous Mast Cell Tumors Vet. Pathol., January 1, 2000; 37(1): 33 - 39. [Abstract] [Full Text] [PDF]

				M. H. Jaffe, G. Hosgood, H. W. Taylor, S. C. Kerwin, C. S. Hedlund, M. K. Lopez, J. R. Davidson, D. M. Miller, and M. Paranjpe Immunohistochemical and Clinical Evaluation of p53 in Canine Cutaneous Mast Cell Tumors Vet. Pathol., January 1, 2000; 37(1): 40 - 46. [Abstract] [Full Text] [PDF]

				R. A. Levine and M. A. Fleischli Inactivation of p53 and Retinoblastoma Family Pathways in Canine Osteosarcoma Cell Lines Vet. Pathol., January 1, 2000; 37(1): 54 - 61. [Abstract] [Full Text] [PDF]